Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Exhibit 99.1

Company Presentation August 2023

This presentation contains "forward-looking statements" relating to future events, and AgPlenus (the “Company”) and its parent, Evogene Ltd. (“Evogene”, and collectively “we”, “us”, “our”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, growing market’s expectations, challenges, business model and potential revenue stream, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”. Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. Forward-Looking Statements

Agenda 01// Vision, challenges & our solution 02// The technology platform 04// Business development 03// Product pipeline 05// Summary

Our Vision Novel and safe crop protection products Design and develop novel and safe crop protection products allowing food security for the rapidly growing world population Our Mission AI and science to boost novel crop protection development To direct and accelerate the development of target-based novel crop protection products, utilizing a revolutionary tech-engine based on AI, combined with a deep understanding of biology and chemistry

Agrochemical Market Growth DriversMarket growth forecast for 2028 ~$92B2023 Est., ~$70B (E.CAGR 4.7%)* *https://www.mordorintelligence.com/ ** with a focus on plant-based food The world’spopulation in 2050 10B of the world’spopulation lives inurban areas 50% is a well proven economical approach for increase of crop yields Agro-chemical pesticide increase in food production to feed the world 60%**

Agrochemical Market Challenges Food Security Risk Increase of Pest Resistance & Regulatory Requirements Reduced tools due to regulatory requirements Resistant pests Increased application rate resulting in environmental damage Long and Expensive Development Time to market 10-12 years Average cost of $286M 160K molecules synthesized Lack of Innovation Decrease in discovery of new pesticides Lack of capabilities to identify protein targets Novel products & an effective product development approach are urgently needed

01 Target Protein Selection 02 Small Molecule Inhibitor Identification Target Protein - an essential protein, that upon loss of its function compromises the organism. The ChallengeTo find a novel, safe, and druggable Target Protein from the thousands of proteins in the relevant organism, with a new mode-of-action (MOA) that will not result in adverse cross-reactivity in beneficial species. Key Product Development Challenges A small molecule inhibitor - is a chemical compound that effectively modulates or inhibits the activity of the target protein. The ChallengeTo find a novel molecule inhibitor out of the billions of potential chemical compounds, that both effectively and selectively affects the target protein.

Our Solution -AI and Science for Novel Crop Protection Addressing environmental safety and selectivity early in discovery Cost-effective, wet screening of only hundreds of compounds Reduced time to market AI- based rapid virtual screening of 1010 compounds Computational prediction of essential druggable proteins Well-provendrug designin-silico approach assimilated into the tech-engine Robustcomputational platform Increase probability of success

Protein Target Selection AgPlenus’ Holistic Discovery Approach 1- under PoC. 2- under development. ‘TargetSelector’1 ‘Evolve’ Target validation ‘PointHit’ in-vitro screening in-vivo screening ‘ActiveSearch’ ‘De-novo SAR’2 Tox & Ag models Pesticide similarity Greenhouse and field studies Small Chemical Molecule Identification Small Chemical Molecule Optimization Predictions verified by wet assays Leading compounds for pre-development

Protein Target Selection AgPlenus’ Holistic Discovery Approach 1- under PoC. 2- under development. ‘TargetSelector’1 ‘Evolve’ Target validation ‘PointHit’ in-vitro screening in-vivo screening ‘ActiveSearch’ ‘De-novo SAR’2 Tox & Ag models Pesticide similarity Greenhouse and field studies Small Chemical Molecule Identification Small Chemical Molecule Optimization Leading compounds for pre-development Predictions verified by wet assays

TargetSelector -A computational approach foridentification of essential proteins Cost-effective and time-efficient approach Addressing environmental safety and selectivity early in discovery 11 Variety of novel targets (less researched)

TargetSelector Essentiality Predicting proteins necessary for the survival, growth, and reproduction of an organism Cellular pathways Connecting the target protein to biological pathways essential for cellular processes Druggability Computational assessment of the likelihood of a small molecule to modulate a target Target-related safety Assessing on-target and off-target safety-related issues Target Selector

TargetValidation Knocking down the targeted protein results in severe growth inhibition *Transgenic Arabidopsis In the presence of target gene silencer inducer No treatment (control)

Protein Target Selection AgPlenus’ Holistic Discovery Approach 1- under PoC. 2- under development. ‘TargetSelector’1 ‘Evolve’ Target validation ‘PointHit’ in-vitro screening in-vivo screening ‘ActiveSearch’ ‘De-novo SAR’2 Tox & Ag models Pesticide similarity Greenhouse and field studies Small Chemical Molecule Identification Small Chemical Molecule Optimization Predictions verified by wet assays Leading compounds for pre-development

PointHit - a Virtual HighThroughput Screening Tool Advantages Highly efficient deep docking of up to 30B compound DB (>400-fold acceleration)* Supplemented with proprietary machine-learning (ML) tools to evaluate bioavailability * Gorgulla et al. Nature. 2020;580(7805):663 Increases structural variability and opportunity to find Hits Reduces the volume of downstream analysis - cost and time-effective Eyeballing Purchase for testing ~100 ~40M Pharmacophoremodels Protein Structure Toxicity Ag models Pharmacophore Docking DeepDocking Cavities Pareto Interactions Pareto Clustering Automatic computational steps User-operated filtration apps ~1M ~30B ~100K ~10K

PointHit - Start-to-End Case Study Identification of novel Hits Clustering -1.2K Ordered 216 40M compound DB Pharmacophore screening – output 2M compounds Docking 900M highly purchasable compounds Ag models 31 in-vitro verified Hits interactions; docking score; cavities output-9K

Protein Target Selection AgPlenus’ Holistic Discovery Approach 1- under PoC. 2- under development. ‘Target Selector’1 ‘Evolve’ Target validation ‘PointHit’ in-vitro screening in-vivo screening ‘ActiveSearch’ ‘De-novo SAR’2 Tox & Ag models Pesticide similarity Greenhouse and field studies Small Chemical Molecule Identification Small Chemical Molecule Optimization Predictions verified by wet assays Leading compounds for pre-development

A proprietary computational SAR tool to streamline Hit and Lead optimization process ActiveSearch - Optimization Tool Input Bio-isosteres generation Ultra large DBpurchasablecompounds Structure based analysis(Docking) Output List of top scoring purchasable compounds molecule/s Identification of bio-isosters substitutes in addition to traditional similarity/ substructure searches Efficient search algorithm in DBs of billions of purchasable molecules

ActiveSearch - Case StudyActiveSearch Yielded Purchasable Active Compounds Distribution of % inhibition by scaffold Comments Pass/Fail Criterion ~95% purchasable Pass Compound availability 57% above the threshold (40% inhibition) 20% above 90% inhibition Pass Compound activity NEW chemicals identified Pass Diversity

Additional CapabilitiesUnder Development Hit & Lead optimization ActiveSearch V.1.1 Improved functionality, addition of features used in analog selection leading to enhanced predictive results Hitdiscovery PointHit V.2.0 Predictive models for Ag activity to increase probability of success Target discovery & prioritization TargetSelector V.2.0 Automate target assessment process to increase speed and predictive success for the selection of commercially relevant novel protein targets Hit & Lead optimization De-Novo Design V.1.0 Design of novel compounds and assessment of synthetic feasibility resulting in fine tuning of products to better serve the target market while minimizing cost of goods

De-novo Design Addressing Lead-to-Candidate challenges De-novo design of new chemical entities: Structure activity relationship analysis (SAR) Synthesis models – computational assessment of ease of synthesis and route of synthesis

DashboardUser-Enabled Software

Our Products Broad Spectrum Herbicide Market opportunity Total herbicide - estimated at $30.3B1 Resistance to current top products Piercing/Sucking Insecticide Market opportunity Total insecticide market – estimated at $18.7B2 Europe ban on insecticide classes Wheat Blotch Fungicide Market opportunity Total fungicide market – estimated at $20.83 Resistance to current top products (‘Strobilurins’) Major markets North America, Latin America Needs in all major global regions Major markets Europe, Asia Needs in all major global regions 1) https://www.mordorintelligence.com/industry-reports/global-herbicides-market-industry?gclid=EAIaIQobChMIqL--hsHMgAMVoJODBx2ZLQeZEAAYAiAAEgLXqvD_BwE Major markets Global 2) https://www.mordorintelligence.com/industry-reports/global-insecticides-market-industry?gclid=EAIaIQobChMIwcXxqcHMgAMVkpCDBx2xiAeyEAAYASAAEgK5mfD_BwE 3) https://www.mordorintelligence.com/industry-reports/global-fungicides-market-industry

Product ProgramName / Type Protein Name Discovery Pre-Development Protein Identification & Selection Hit Identification Hit & LeadOptimization HERBICIDES Broad spectrum APTH 1 Corteva Collaboration INSECTICIDES Piercing/sucking APTI 1 FUNGICIDES Wheat blotch AgPlenus Pipeline S1 S1 S2 S3 Confidential Confidential Completed In process Completed In process In process S- scaffold

Business Model LicensingModel Development up to Lead optimization, by AgPlenus Hand off to partner Revenue via license, milestones, royalties Collaboration Model Co-development utilizing AgPlenus’ and partner’s capabilities Flexible entry point along development path Revenue via upfront fee, R&D reimbursement, milestones, royalties Joint Product Model Co-development starting at identification of market target Revenue via R&D reimbursement, milestones, royalties

Collaboration Agreement Joint Product Development Licensing Agreement Registration & Commercialization Development Pre-Development Hit and Lead Optimization HitIdentification TargetSelection TargetIdentification Go to Market Strategy Partnering Opportunities AgPlenus Partner License fees R&D reimbursement Milestone payments Royalties

Collaboration Agreement License to Corteva Corteva has exclusive license to products of collaboration AgPlenus receives research fees, milestones & royalties upon commercialization Develop new MoA herbicidesto target resistant weeds Started in March 2020 AgPlenus to discover & optimize herbicide candidates Corteva to conduct testing & product development

Partnership Opportunities Full R&D capabilities companies New projects, identified targets, SAR, pipeline projects Opportunities Interest in partnering for earlier innovation Pipelineprojects Opportunities Generic companies Pipelineprojects Asian entities Opportunities Discovery companies Target identification,hit ID,optimization MoA Opportunities

The Management Team Innovative & Experienced Management Team Brian Ember, PhD | CEO Previous positions: Biotalys, Head of Global Portfolio Management & Head of Marketing AgriMetis, Business Development Merav Beiman, PhD | VP R&D Previous positions: ImmPACT-Bio, CEO Ferring, R&D Compugen, R&D QBI, R&D Mirit Ram, MSc | VP Portfolio Management Previous positions: Evogene, PM FMC, PM HP, R&D Yaron Elad | CFO Previous positions: Yamba Group Int. Ltd, CFO Recoly NV, CFO e-Sim Ltd., CFO Liat Foigel-Wejgman | VP HR Previous positions: Evogene, HR Director

Board Experienced Board of Directors Ofer Haviv | Chairman of The Board Evogene, President & CEO Robert A. Woods | Director Former Chair of Marrone Bio Innovations, CEO and Chair of Targeted Growth Inc. Former Chair of Syngenta Corp, US Adrian Percy | Director North Carolina Plant Sciences Initiative (N.C. PSI), Executive Director Board of Directors: Evogene, BioLumic, Nufarm, FA Bio Previously: UPL, CTO Previously: Head of R&D, Bayer Eran Kosover | Director Atera Networks Previously: AgPlenus Ltd., CEO Previously: Evogene, EVP & GM Crop Protection Sassi Masliah | Director Evogene, VP Corporate Development

Summary Target-based design with new MoA for sustainable and resistance breaking products Continuous incremental tech platform improvements Large molecule database provides wide chemical space Combined computational and biological platforms Higher probability of success Flexible business model 31